NUWIQ® – Efficacy
POWERFUL BLEEDING CONTROL
Prophylaxis with NUWIQ Markedly Reduced Bleeding Frequency1,2
In Clinical Trials of Standard Prophylaxis with NUWIQ in Adult (N=32) and Pediatric (N=59) Patients Treated for ≥6 Months1*
Adults and Children
Median ABR for All Bleeds is 0.9
Median ABR for All Bleeds is 1.9
All Patients Experienced Fewer Bleeds with NUWIQ Prophylaxis vs On-Demand Treatment with Another FVIII Product1,2†
Patients were switched from on-demand therapy (pre-study) with another FVIII product to prophylaxis with NUWIQ.
With 1 Infusion
With 1 or 2 Infusions
In 100% of minor surgeries hemostasis rated as "excellent"
In 92% of major surgeries hemostasis rated as "excellent" or "good"
- NUWIQ full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.
- Data on file. Paramus, NJ: Octapharma USA, Inc; 2015.
- Valentino LA, et al. Haemophilia.2014;20 (Suppl. 1), 1–9.
- Kessler C, et al. Haemophilia. 2015;21(Suppl. 1): 1-12.